Open access peer-reviewed Edited Volume

Non-alcoholic Fatty Liver Disease - New-Insight and Glance Into Disease Pathogenesis

Ju-Seop Kang

Hanyang University

Dr.Kang is a pioneering researcher and contributor to new drug development & research and clinical pharmacology. He is a reformer for establishing research integrity in Hanyang University, also an appraisal and activist for appropriate evaluation and compensation for medical accidents in K-medi.


Immunity in NAFLD Immunologic Targets in NAFLD Hepatic Lymphocyte in NAFLD Metabolomics in NAFLD Hepatic Lipid Homeostasis in NAFLD NAFLD and Hyperlipidemia Gut Microbiota in NAFLD Diet Manipulation in Control of NAFLD Obesity and NAFLD Lifestyle and Diet Control in NAFLD Control Novel Therapeutic and Diagnostic Approaches for NAFLD

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

This book will deal with the basic concepts and immunopathological aspects of the pathogenesis of non-alcoholic fatty liver diseases (NAFLD), which is a global burden on human health. In particular, the relationship between NAFLD and systemic metabolic syndrome, which is highly likely to coexist, and the relationship between the intestinal microbiota and the immune environment is described. In addition, in a situation where there is no clear treatment yet, the status of treatment development in the clinical trial pipeline will be described.

A summary of its contents is as follows.
• As a consequence of the pandemic spread of obesity, NAFLD is one of the most important causes of liver disease worldwide in adults and children. The large volume of patients sets NAFLD apart from other liver diseases, meaning the major focus of clinical care is discerning those at the highest risk of progressive liver disease
• Because the overweighting in childhood and adolescence is associated with an increased risk of NAFLD later in life, the threshold of liver-related morbidity and/or mortality is reached at a younger age. Patients with NAFLD have a high risk of liver-related morbidity and mortality along with metabolic comorbidities and might place a growing strain on healthcare systems
• Whereas animal studies have demonstrated a potential causal role of gut microbiota in NAFLD, human studies have only just started to describe microbiome signatures in NAFLD.
• Proteobacteria are consistently enriched in steatosis and non-alcoholic steatohepatitis.
• Discrepant microbiome signatures across studies could be linked to the heterogeneity of geographical regions, ethnicity, population characteristics, microbiome sequencing tools, NAFLD diagnostic tools, disease spectrum, drug consumption, and circadian rhythm.
• The composition of the diet, in particular the types of lipids and carbohydrates, have an important role in the progression of NAFLD to NASH and fibrosis
• A complex interplay between the environment (especially diet), host genetics, and the gut microflora is crucial for the development and progression of NAFLD
• Activation of the innate immune system has an essential role in maintaining homeostasis and liver regeneration, as well as disease pathogenesis, acting in a cooperative rather than independent fashion
• Discoveries that characterized the importance of cell death in NAFLD progression triggered the development of novel therapeutic and diagnostic approaches for NAFLD
• Various types of cell death contribute to the development of NAFLD; extensive crosstalk and biochemical cooperation exists between these cell death pathways to drive disease progression
• Chronic hepatic inflammation represents the driving force in the evolution of nonalcoholic steatohepatitis (NASH) to liver fibrosis and/or cirrhosis.
• In both humans and rodents, NASH is characterized by B cell and T cell infiltration of the liver as well as by the presence of circulating antibodies targeting antigens originating from oxidative stress.
• Alterations in regulatory T cell and hepatic dendritic cell homeostasis have a role in triggering immune responses during the progression of NASH.
• While NAFLD progression to non-alcoholic steatohepatitis is becoming the leading cause of end-stage liver failure, the leading causes of death in patients with NAFLD are complications of cardiometabolic disease and a tight relationship exists between NAFLD, insulin resistance, and type II diabetes mellitus.
• A NAFLD has become the most common liver disease globally, yet there are currently no approved therapies and It is likely that developing therapeutics that target both NAFLD and cardiometabolic risk factors might be extremely beneficial.

Publishing process

Book initiated and editor appointed

Date completed: April 14th 2022

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline Extended: Open for Submissions

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Approved chapters written in full and submitted

Deadline for full chapters: July 11th 2022

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: September 29th 2022

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: November 28th 2022

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Ju-Seop Kang

Hanyang University

.1993-Now: Professor, Department of pharmacology, College of Medicine, Hanyang University . 2008-Now : CEO Pharmbrain Co. .2010-Now: Director, Institute of New Drug Development & Research, Hanyang University Medical Center. .2018-Now: Vice president and Director in Committee of Text Publication, The Korean Society of Pharmacology. .2010-Now: Appraisal member and advisory member, Korea Medical Dispute Mediation and Arbitration Agency

View profile

Book chapters authored 2

Books edited 0

Introducing your Author Service Manager

Ms. Martina Ivancic

As an Author Service Manager, my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact.

Ask a question

Book will be abstracted and indexed in